Collegium Pharmaceutical, Inc.
COLL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $209,361 | $188,000 | $177,757 | $181,949 |
| % Growth | 11.4% | 5.8% | -2.3% | – |
| Cost of Goods Sold | $80,190 | $79,616 | $80,433 | $83,661 |
| Gross Profit | $129,171 | $108,384 | $97,324 | $98,288 |
| % Margin | 61.7% | 57.7% | 54.8% | 54% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $65,551 | $73,637 | $76,423 | $63,091 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$358 | -$786 | -$2,914 |
| Operating Expenses | $65,551 | $73,279 | $75,637 | $60,177 |
| Operating Income | $63,620 | $35,105 | $21,687 | $38,111 |
| % Margin | 30.4% | 18.7% | 12.2% | 20.9% |
| Other Income/Exp. Net | -$20,184 | -$18,080 | -$18,565 | -$20,842 |
| Pre-Tax Income | $43,436 | $17,025 | $3,122 | $17,269 |
| Tax Expense | $11,929 | $5,042 | $705 | $4,733 |
| Net Income | $31,507 | $11,983 | $2,417 | $12,536 |
| % Margin | 15% | 6.4% | 1.4% | 6.9% |
| EPS | 1 | 0.38 | 0.076 | 0.39 |
| % Growth | 163.2% | 400% | -80.5% | – |
| EPS Diluted | 0.84 | 0.34 | 0.074 | 0.35 |
| Weighted Avg Shares Out | 31,571 | 31,811 | 31,794 | 32,079 |
| Weighted Avg Shares Out Dil | 39,440 | 39,076 | 32,840 | 40,110 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3,116 | $2,383 | $2,225 | $1,812 |
| Interest Expense | $21,767 | $20,463 | $20,790 | $22,654 |
| Depreciation & Amortization | $56,506 | $56,608 | $56,564 | $56,512 |
| EBITDA | $121,709 | $94,096 | $80,476 | $96,435 |
| % Margin | 58.1% | 50.1% | 45.3% | 53% |